| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10013568 | HBV | ENSG00000151617.17 | protein_coding | EDNRA | No | No | 1909 | P25101 |
| TVIS20026127 | HPV | ENSG00000151617.17 | protein_coding | EDNRA | No | No | 1909 | P25101 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | EDNRA |
|---|---|
| DrugBank ID | DB12548 |
| Drug Name | Sparsentan |
| Target ID | BE0000521 |
| UniProt ID | P25101 |
| Regulation Type | antagonist |
| PubMed IDs | 15634011; 29142983; 29947527 |
| Citations | Murugesan N, Gu Z, Fadnis L, Tellew JE, Baska RA, Yang Y, Beyer SM, Monshizadegan H, Dickinson KE, Valentine MT, Humphreys WG, Lan SJ, Ewing WR, Carlson KE, Kowala MC, Zahler R, Macor JE: Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics. J Med Chem. 2005 Jan 13;48(1):171-9. doi: 10.1021/jm049548x.@@Komers R, Gipson DS, Nelson P, Adler S, Srivastava T, Derebail VK, Meyers KE, Pergola P, MacNally ME, Hunt JL, Shih A, Trachtman H: Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET). Kidney Int Rep. 2017 Mar 4;2(4):654-664. doi: 10.1016/j.ekir.2017.02.019. eCollection 2017 Jul.@@Davenport AP, Kuc RE, Southan C, Maguire JJ: New drugs and emerging therapeutic targets in the endothelin signaling pathway and prospects for personalized precision medicine. Physiol Res. 2018 Jun 27;67(Suppl 1):S37-S54. doi: 10.33549/physiolres.933872. |
| Groups | Approved; Investigational |
| Direct Classification | Biphenyls and derivatives |
| SMILES | CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C(COCC)=C1)C1=CC=CC=C1S(=O)(=O)NC1=NOC(C)=C1C |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL539423 |
